Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients.
antiobesity drug
bariatric surgery
liraglutide
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
10
10
2018
revised:
16
12
2018
accepted:
02
01
2019
pubmed:
16
2
2019
medline:
30
5
2020
entrez:
16
2
2019
Statut:
ppublish
Résumé
In this study we prospectively collected data on the use of liraglutide 3 mg in obese Arab patients. As part of routine care, 2092 patients were dispensed liraglutide 3 mg. Median age was 38 years and 77% were women. Median baseline weight was 95 kg and body mass index was 36.6 kg/m
Substances chimiques
Anti-Obesity Agents
0
Liraglutide
839I73S42A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1498-1501Informations de copyright
© 2019 John Wiley & Sons Ltd.